Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
PEPG | US
0.05
3.05%
Healthcare
Biotechnology
30/06/2024
13/04/2026
1.69
1.66
1.72
1.61
PepGen Inc. a clinical-stage biotechnology company focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51 an EDO peptide that id in Phase I clinical trial to treat individuals with Duchenne muscular dystrophy (DMD). The company is also developing PGN-EDODM1 an EDO peptide-conjugated PMO which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1 as well as EDO therapeutic candidates such as PGN-EDO53 PGN-EDO45 and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is headquartered in Boston Massachusetts.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
293.4%1 month
210.3%3 months
156.5%6 months
130.3%-
-
1.88
0.13
0.10
-3.11
-
-
-94.36M
55.08M
55.08M
-
-
-
-
-58.97
7.73
5.64
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
3.31
Range1M
4.18
Range3M
5.82
Rel. volume
0.46
Price X volume
1.86M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Equillium Inc | EQ | Biotechnology | 1.7 | 60.22M | -5.56% | n/a | 2.71% |
| VANI | VANI | Biotechnology | 1.05 | 58.02M | 0.96% | n/a | 84.10% |
| CDIO | CDIO | Biotechnology | 1.88 | 57.53M | 2.73% | n/a | 28.31% |
| ImmuCell Corporation | ICCC | Biotechnology | 7.11 | 55.69M | 0.49% | n/a | 67.52% |
| THL Credit Inc. 6.75% Notes du | TCRX | Biotechnology | 1.02 | 54.03M | -2.86% | n/a | 35.68% |
| TPST | TPST | Biotechnology | 2.14 | 53.94M | 4.39% | n/a | 119.58% |
| Sangamo Therapeutics Inc | SGMO | Biotechnology | 0.257 | 53.51M | 2.31% | n/a | 122.82% |
| OKYO Pharma Limited | OKYO | Biotechnology | 1.53 | 51.77M | 1.32% | n/a | -107.88% |
| Clene Nanomedicine Inc | CLNN | Biotechnology | 6.48 | 51.59M | 6.06% | n/a | -6472.02% |
| Akari Therapeutics Plc | AKTX | Biotechnology | 4.2475 | 51.58M | 10.90% | n/a | -27.01% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 10.4 | 15.84M | -11.56% | n/a | 204.46% |
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.8799 | 12.86M | -18.53% | 0.03 | 16.03% |
| REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 0.6 | 11.59M | -0.17% | n/a | 58.43% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.33 | 3.40M | -0.75% | n/a | 17.32% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.2276 | 2.17M | -10.25% | n/a | 19.98% |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 2.07 | 1.14M | -0.96% | n/a | 0.00% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -3.11 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 1.88 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 156.54 | 72.80 | Riskier |
| Debt to Equity | 0.13 | -1.23 | Expensive |
| Debt to Assets | 0.10 | 0.25 | Cheaper |
| Market Cap | 55.08M | 3.66B | Emerging |